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HEALTH CARE COSTS AND UTILIZATION FOR PRIVATELY INSURED PATIENTS
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OBJECTIVES:Describe costs and utilization patterns of corticosteroid (CTS), immu-
nosuppressive (IMS), and biologic (BIO) treatment use in patients with chronic
non-infectious uveitis. Costs and utilization of CTS, IMS and BIO indicate economic
burden but have not been studied in a large sample. METHODS: Patients with 31
NPSU diagnosis (ICD-9-CM 360.x–364.x, excluding infectious uveitis) by an ophthal-
mologist or 32 by a primary care physician, under age 65, with continuous insur-
ance coverage during a six-month baseline were selected from a privately insured
claims database (N80.7 million). Sample index dates were defined as the first
prescription/administration of CTS, IMS, or BIO between 2003-2009. CTS patients
had 32 10-day or 31 30-day scripts. Analysis was in a per-member-per-month
(PMPM) framework based on treatment episodes, defined as continuous medica-
tion usewithin the same class.Wilcoxon rank-sum and chi-square tests were used
for comparisons of costs and categorical outcomes. RESULTS: CTS (N19,426), IMS
(N5,466) and BIO (N1,694) samples were selected; average time on continuous
therapy (i.e., treatment episode duration) was 1.79, 3.66, and 8.18 months (p0.05
across groups). Baseline Charlson Comorbidity Index was highest for BIO (0.83),
then IMS (0.78), then CTS (0.039) (p0.05 across groups). Baseline PMPM inpatient
admission rates were 0.021 for CTS, 0.044 for IMS, and 0.045 for BIO (p0.05 across
groups); study period values were 0.032, 0.048, and 0.024, respectively (p0.05 CTS
different vs. both). Emergency room visits had a similar ordering. Baseline average
PMPM costs for CTS were $717; IMS were $1738; and BIO were $1439 (p0.05 across
groups). Study period PMPM costs excluding drug or biologic costs were $974 for
CTS; were $1592 for IMS; and were $918 for BIO (p0.05 across groups).
CONCLUSIONS: BIO had the best relative change in outcomes, followed by IMS.
There could be underuse of these products relative to CTS.
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PRODUCTIVITY LOSSES ASSOCIATED WITH VISION IMPAIRMENT IN CANADA
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OBJECTIVES: In Canada, visual impairment is highly prevalent and is associated
with a substantial socioeconomic impact on patients, and especially on caregivers.
The objective of this study was to explore the current evidence on productivity
losses associated with vision impairment, such as caregiver support, and to esti-
mate the cost of these productivity losses in Canada according to visual impair-
ment severity.METHODS: A literature search was conducted in MedLine and Em-
base databases using the keywords “visual acuity,” “vision loss,” “burden,” and
“cost.” Studies included in the search dated from January 2000 to June 2011. Data
were extracted from studies that reported productivity losses according to vision
impairment severity and in terms of duration of work lost. The mean number of
hours requiring help per year reported in the studies wasmultiplied by the average
Canadian hourly wage ($CAD22.85 in May 2011) to calculate the average costs as-
sociated with productivity losses. RESULTS: In all, 885 articles addressing the bur-
den of vision impairmentwere retrieved. Of these, two reported productivity losses
in terms of duration of work lost and according to the severity of vision impair-
ment. In both studies, visual impairment severity was categorized by levels of
visual acuity (VA). The duration of work lost increased with decreasing visual acu-
ity. On average, patients incurred annual productivity loss-related costs ranging
from $CAD347 to $CAD48,183 for VA scores ranging from 20/10 to worse than
20/320, respectively. CONCLUSIONS: Productivity losses and related costs associ-
ated with vision impairment are substantial, and they correlate with vision loss
severity. Caregiver-related costs are the largest component of productivity losses.
PSS9
ECONOMIC BURDEN OF WET AGE-RELATED MACULAR DEGENERATION
(WAMD) IN URBAN CHINA
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OBJECTIVES: This study aims to understand the direct and indirect cost of patients
with wAMD in urban China, and to assess the economic burden of wAMD in real
world from societal perspective. METHODS: A cross-sectional study was carried
out in 15 key eye centers and hospitals in 4 major cities of China (Beijing, Guang-
zhou, Shanghai and Chengdu) fromAugust 2010 through April 2011. Study subjects
were face-to-face interviewed by trained interviewers using structured question-
naires. Data of patients’ demographics, disease history, treatment pattern and
economic burden were collected based on medical charts and patient self-reports.
Utilities were calculated by regression formula under various measures, including
EQ-5D andNEI-VEF-25. Indirect cost was estimated by GDP per capitamultiplied by
DALYs and productivity weight. All cost were adjusted according to 2010 price
index in China. No discount was applied. RESULTS: Of the 417 eligible patients,
average agewas 67.93 (11.04) years old and 51.32%weremale. The averagewAMD
onset agewas 64.87(11.72) years old with average duration of 2.93 years. A total of
130 patients were bilateral, and a total of 547 wAMD eyes were identified. On
average, it costs 3,278 CNY per wAMD outpatient visit. Economic burden of wAMD
per eye per year was 29,640 CNY. Based on average life expectancy at 72 years old
from national statistics, economic burden of entire course of wAMD per eye was
estimated to be 207,450 CNY. Given the wAMD prevalence rate at 0.34% among
Chinese above 45 years old, the potential national burden of wAMD was 53.39
billionCNYper year, inwhich directmedical costwas 16.81 billionCNY, accounting
for 31.49%. CONCLUSIONS: In urban China, the economic burden for wAMD is
heavy both for patients and the society, while indirect cost account for majority
part of the burden.
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OBJECTIVES: To perform a cost-effectiveness analysis of Ranibizumab 0.5mg vs
Verteporfin photodynamic therapy (PDT) for the treatment of nAMD from the IMSS
perspective. METHODS: A Markov model was designed to analyze the disease in
patients 40 years-old. A systematic review was performed to obtain transition
probabilities used in the model. A hypothetical cohort was built from a retrospec-
tive database of patients with nAMD diagnosis at the IMSS*. The model identifies 4
states of changes in vision: Stability, Increase, Loss, Severe-Loss. Cycle duration
was 1 month, time horizon 5 years. Efficacy was evaluated by visual acuity gains
(VAG) of  15 letters; % of patient withdrawals due to adverse events (AEs) and
average utility score gain. Resource use of direct medical costs was identified from
expert review and valuated according to the Unitary Costs List published by the
IMSS. Sensitivity analysis was performed using a bootstrap technique. RESULTS:
Ranibizumab has the highest rate of patients with VAG 15 letters with 25.23%
versus 5.95% for Verteporfin PDT.Withdrawals due to AEs were 3.91% versus 5.05%
for Ranibizumab and Verteporfin PDT. Utilities were greater with Ranibizumab of
0.216 vs 0.143 for Verteporfin PDT. The total annual cost per treatment was higher
with Verteporfin PDT US$78,983.19 than Ranibizumab US$71,643.56. Ranibizumab
drug acquisition was US$124.6 lower than Verteporfin PDT. The costs were similar
between the two therapies in the Stability and Increase States; whereas in the Loss
and Severe-Loss, Ranibizumab had the lower cost for 29.8% and 16.6% less than
Verteporfin PDT. Sensitivity analysis showed absolute dominance and cost-effec-
tiveness of Ranibizumab in around 50% and 100% of the times, respectively.
CONCLUSIONS: For patients with nAMD, treatment with Ranibizumab is an effec-
tive and cost-saving option comparedwith Verteporfin PDT, allowing savings of up
to US$532 per patient-year which represents 9.3% of the total cost. Results are
consistent with previous analysis.
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OBJECTIVES: Biologic treatment after systemic drugs fail in psoriasis is indicated
for obtaining clinical response. Etanercept effectiveness is not lost in retreatment
regimens, which allows continuous or paused therapeutic schemes. The inclusion
of etanercept in the private health care system practice represents a breakthrough
to psoriasis treatment in Brazil. This study aims to perform cost-effectiveness and
cost-utility analysis of biologic alternatives for moderate to severe psoriasis in
Brazil, from a private payer’s perspective. METHODS: A decision-tree model sim-
ulates psoriasis evolution after treatment with etanercept paused (50mg twice a
week for 12 weeks, followed by 25mg twice a week; 12-week treatment cycle and
12-week interruption), adalimumab (80mg at first week, followed by 40mg in the
second week, and then 40mg every two weeks) or infliximab (5mg/kg at weeks 0, 2
and 6 and then every 8weeks) and their associated costs in a 96-week time horizon.
Therapy continuation or switch was evaluated at week 24. Effectiveness measures
were PASI 75 success rate and quality adjusted life years (QALY) gained. Costs
included biologicals,medical follow-up and adverse eventsmanagement, collected
from Brazil private official databases (values represented 2010 USD). Probabilistic
sensitivity analyses were performed troughMonte Carlo simulation. A 5% discount
ratewas applied for costs and benefits.RESULTS: Effectiveness resulted in [PASI 75,
QALY] etanercept [51.3%, 1.5360], adalimumab [50.5%, 1.5339] and infliximab
[37.2%, 1.5001]. Treatment costs were 90,644USD, 110,663USD and 121,697USD, re-
spectively. Etanercept paused represented the least costly in all comparisons:
20,019USD and 31,054USD less than adalimumab and infliximab, respectively. Ac-
ceptability curves showed etanercept paused as the most cost-effective biologic.
CONCLUSIONS: In this analysis, etanercept presented the greatest effectiveness in
paused therapeutic scheme. Due to its lower costs, etanercept showed to be cost-
saving regarding PASI 75 success rate and QALY’s gained over other biologic treat-
ments in psoriasis management at Brazil private healthcare system.
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ECONOMIC ANALYSIS OF ETANERCEPT AS CONTINUOUS OR PAUSED THERAPY
IN MODERATE TO SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN
VENEZUELA
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OBJECTIVES: Biologic treatment after systemic drugs fail in psoriasis is indicated
for obtaining clinical response, what could avoid associated comorbidities. Regard-
ing biological drugs approved for psoriasis, etanercept effectiveness is not lost in
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